Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan. 

CEO
Christophe P. Weber
CEOChristophe P. Weber
Employees
47,455
Employees47,455
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,455
Employees47,455

TAK Key Statistics

Market cap
50.27B
Market cap50.27B
Price-Earnings ratio
39.28
Price-Earnings ratio39.28
Dividend yield
3.76%
Dividend yield3.76%
Average volume
3.22M
Average volume3.22M
High today
$16.03
High today$16.03
Low today
$15.85
Low today$15.85
Open price
$16.00
Open price$16.00
Volume
3.94M
Volume3.94M
52 Week high
$18.90
52 Week high$18.90
52 Week low
$12.99
52 Week low$12.99

TAK News

Simply Wall St 4h
Is Zasocitinib’s Phase 3 Beat And New Shelf Filing Altering The Investment Case For Takeda Pharmaceutical? - simplywall.st

...

Is Zasocitinib’s Phase 3 Beat And New Shelf Filing Altering The Investment Case For Takeda Pharmaceutical? - simplywall.st
Benzinga 1d
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med

Head-To-Head Trial Meets Endpoints In the LATITUDE Atlas head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the prim...

Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med
TipRanks 1d
Takeda announces results for Phase 3 study of TAK-279

Takeda (TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib, TAK-279, an investigational,...

Analyst ratings

67%

of 15 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More TAK News

TipRanks 3d
FDA accepts Takeda’s application for intravenous Entyvio

Takeda (TAK) announced the U.S. Food and Drug Administration has accepted for review its supplemental Biologics License Application for intravenous ENTYVIO for...

TipRanks 3d
Takeda’s TAK-360 Narcolepsy Trial Moves Forward, Expanding Its Specialty CNS Pipeline

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is moving ahead with a phase 2 trial of TAK-360 for adults with...

TipRanks 4d
Takeda to Issue Shares for Global Employee Long-Term Incentive Plan

An update from Takeda Pharmaceutical Co ( (JP:4502) ) is now available. Takeda Pharmaceutical will issue 10,892,917 new shares and dispose of 6,096,159 treasur...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.